<DOC>
	<DOCNO>NCT01512758</DOCNO>
	<brief_summary>This open-label , multicenter , phase 1 study alisertib East Asian patient ( eg , patient country include limited Singapore , Hong Kong , Taiwan , South Korea ) either relapsed refractory advance solid tumor lymphomas effective standard treatment available .</brief_summary>
	<brief_title>A Study Alisertib ( MLN8237 ) Adult East Asian Patients With Advanced Solid Tumors Lymphomas</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<criteria>Male female East Asian patient 18 year old Histologically cytologically confirm metastatic and/or advance solid tumor lymphomas effective standard treatment available Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 Expected survival longer 3 month study enrollment Radiographically clinically evaluable tumor Female patient post menopausal least 1 year , surgically sterile , agree practice 2 effective method contraception 30 day last dose study drug agree abstain heterosexual intercourse Male patient agree practice effective barrier contraception 6 month last dose alisertib agree abstain heterosexual intercourse Voluntary write consent Female patient lactate pregnant Treatment investigational product , systemic antineoplastic treatment , antineoplastic treatment glucocorticoid within 21 day precede first dose alisertib Treatment nitrosoureas , mitomycin C , rituximab , alemtuzumab , unconjugated antibody treatment within 42 day ( 21 day clear evidence progressive disease ) Medical condition require daily , chronic , regular use proton pump inhibitor H2receptor antagonists Treatment radioimmunoconjugates ibritumomab tiuxetan tositumomab within 56 day precede first alisertib dose Major surgery within 14 day precede first dose alisertib Lifethreatening uncontrolled medical illness unrelated cancer Known gastrointestinal ( GI ) disease procedure could interfere oral absorption tolerance alisertib Inability swallow capsule Inadequate bone marrow organ function Diagnosed treat another malignancy within 2 year first dose alisertib , previously diagnose another malignancy radiographic biochemical marker evidence active disease . In case prior prostate cancer treat radiotherapy , prostate specific antigen ( PSA ) may detectable , must &lt; 1 ng/mL . Patients completely resect basal cell carcinoma , squamous cell carcinoma skin , situ malignancy type exclude Other severe acute chronic medical psychiatric condition , include uncontrolled diabetes , laboratory abnormality Known suspect human immunodeficiency virus ( HIV ) positive hepatitis B surface antigenpositive status , know suspect active hepatitis C infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>East Asian Patients</keyword>
	<keyword>Advanced solid tumor</keyword>
	<keyword>Lymphomas</keyword>
	<keyword>MLN8237</keyword>
	<keyword>Alisertib</keyword>
	<keyword>Aurora A Kinase Inhibitor</keyword>
</DOC>